Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus
- PMID: 16973389
- DOI: 10.1016/j.immuni.2006.07.013
Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus
Abstract
Antibodies (Abs) to RNA- and DNA-containing autoantigens are characteristic of systemic lupus erythematosus (SLE). We showed previously that Toll-like receptor (TLR) 9, recognizing DNA, is required for the spontaneous generation of DNA autoantibodies, but not for the development of lupus nephritis in susceptible mice. We report that lupus-prone mice deficient in TLR7, a receptor for ssRNA, failed to generate Abs to RNA-containing antigens (Ags) such as Smith (Sm) Ag. TLR9 and TLR7 also had dramatic effects on clinical disease in lupus-prone mice. In the absence of TLR9, autoimmune disease was exacerbated, lymphocytes and plasmacytoid DCs were more activated, and serum IgG and IFN-alpha were increased. In contrast, TLR7-deficient mice had ameliorated disease, decreased lymphocyte activation, and decreased serum IgG. These findings reveal opposing inflammatory and regulatory roles for TLR7 and TLR9, despite similar tissue expression and signaling pathways. These results have important implications for TLR-directed therapy of autoimmune disease.
Comment in
-
Tolling for autoimmunity-prime time for 7.Immunity. 2006 Sep;25(3):397-9. doi: 10.1016/j.immuni.2006.08.011. Immunity. 2006. PMID: 16979573
Similar articles
-
Critical role of TLR7 in the acceleration of systemic lupus erythematosus in TLR9-deficient mice.J Autoimmun. 2010 Jun;34(4):339-48. doi: 10.1016/j.jaut.2009.11.001. Epub 2009 Nov 26. J Autoimmun. 2010. PMID: 19944565
-
Toll-like receptor 9-independent aggravation of glomerulonephritis in a novel model of SLE.Int Immunol. 2006 Aug;18(8):1211-9. doi: 10.1093/intimm/dxl067. Epub 2006 Jun 23. Int Immunol. 2006. PMID: 16798839
-
Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms.Eur J Immunol. 2007 Dec;37(12):3582-6. doi: 10.1002/eji.200737815. Eur J Immunol. 2007. PMID: 18034431
-
Emerging roles of TLR7 and TLR9 in murine SLE.J Autoimmun. 2009 Nov-Dec;33(3-4):231-8. doi: 10.1016/j.jaut.2009.10.001. Epub 2009 Oct 21. J Autoimmun. 2009. PMID: 19846276 Review.
-
Toll-like receptor activation in the pathogenesis of systemic lupus erythematosus.Ann N Y Acad Sci. 2005 Dec;1062:242-51. doi: 10.1196/annals.1358.027. Ann N Y Acad Sci. 2005. PMID: 16461805 Review.
Cited by
-
Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9.Nucleic Acids Res. 2013 Apr 1;41(6):3947-61. doi: 10.1093/nar/gkt078. Epub 2013 Feb 8. Nucleic Acids Res. 2013. PMID: 23396449 Free PMC article.
-
The Trinity of cGAS, TLR9, and ALRs Guardians of the Cellular Galaxy Against Host-Derived Self-DNA.Front Immunol. 2021 Feb 11;11:624597. doi: 10.3389/fimmu.2020.624597. eCollection 2020. Front Immunol. 2021. PMID: 33643304 Free PMC article. Review.
-
Sexual dimorphism in autoimmunity.J Clin Invest. 2015 Jun;125(6):2187-93. doi: 10.1172/JCI78082. Epub 2015 Apr 27. J Clin Invest. 2015. PMID: 25915581 Free PMC article. Review.
-
Scavenging nucleic acid debris to combat autoimmunity and infectious disease.Proc Natl Acad Sci U S A. 2016 Aug 30;113(35):9728-33. doi: 10.1073/pnas.1607011113. Epub 2016 Aug 15. Proc Natl Acad Sci U S A. 2016. PMID: 27528673 Free PMC article.
-
Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway.Clin Transl Immunology. 2016 May 13;5(5):e79. doi: 10.1038/cti.2016.26. eCollection 2016 May. Clin Transl Immunology. 2016. PMID: 27350879 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases